N 0728
Alternative Names: N-0728Latest Information Update: 06 Sep 2024
At a glance
- Originator Eurofarma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Benign prostatic hyperplasia
Most Recent Events
- 09 Aug 2024 Preclinical trials in Benign prostatic hyperplasia in Brazil (PO)
- 09 Aug 2024 Eurofarma Laboratorios plans a phase III BENIPRO trial for Benign prostatic hyperplasia in Brazil (PO, Tablet) (NCT06546735)